Amicus Q1 revenue $110.4M (+28% YoY); raises Galafold growth guidance to 13-17%

AMICUS THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.16 revenue$110,403,000

Total revenue $110.4M, up 28% YoY; Galafold net sales $99.4M (+15% YoY).
Pombiliti+Opfolda net sales $11.0M, up 30% from Q4 2023; over 155 patients on/commercial treatment.
GAAP net loss $48.4M ($0.16/sh); non-GAAP net loss $4.6M ($0.02/sh), improved from $16.8M loss in Q1 2023.
Raises full-year Galafold revenue growth guidance to 13-17% (from 11-16%); total revenue growth guided 25-30%.
Cash and securities $239.6M; reiterates full-year non-GAAP profitability projected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AMICUS THERAPEUTICS, INC. updated its the first quarter ended March 31, 2024 guidance (raised).

Period: the first quarter ended March 31, 2024
Guidance: raised
Result: reported results

Exact text from the filing

On May 9, 2024, Amicus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-059089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.